According to European Medicines Agency (EMA) indications, two multikinase inhibitors (MKIs) (i.e. vandetanib and cabozantinib) and one highly selective RET inhibitor (i.e. selpercatinib) have been approved for the treatment of progressive advanced/metastatic MTC (2). This evidence concerns the gene RET and medullary thyroid gland carcinoma.